Chronic hand eczema
Feb 14, 2023
Leo Pharma’s Hand Eczema Clinical Trial Updates; GSK’s PD-1 inhibitor Jemperli Approval; Roche Announces Phase III Result of Vabysmo; FDA Accepts NDA for Aldeyra’s reproxalap; RMAT and Fast Track Designations to IASO Bio’s CT103A; Orphan Drug Designation to Jubilant Therapeutics’s JBI-778
Leo Pharma Announces Positive Results of Phase III Hand Eczema Clinical Trial LEO Pharma A/S, a global leader in medical dermatology, announced that the DELTA 2 trial yielded positive results. DELTA 2 is the second of two pivotal phase III clinical trials involving delgocitinib cream, an investigational topical ...
Read More...
Jan 06, 2020
Chronic Hand Eczema Market Analysis and Forecast
Eczema is an umbrella term comprising skin disorders characterised by dry, discoloured, itchy and inflamed skin. Hand eczema (HE) are non-infectious, inflammatory cutaneous lesions and belongs to the most common skin disorder affecting the hands. In a substantial number of patients, HE can develop into a chronic...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
